HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) has a beta value of 1.73 and has seen 1,738,929 shares traded in the recent trading session. The company, currently valued at $43.05 Million, closed the recent trade at $0.6914 per share which meant it lost $0 on the day or 1.76% during that session. The HTGM stock price is -137.2% off its 52-week high price of $1.64 and 61.38% above the 52-week low of $0.267. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.7 Million shares traded. The 3-month trading volume is 4.35 Million shares.
The consensus among analysts is that HTG Molecular Diagnostics, Inc. (HTGM) is an Overweight stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 1 out of 4 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.08.
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) trade information
Despite being -0.74% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Jun 24 when the HTGM stock price touched $0.82 or saw a rise of 19.78%. Year-to-date, HTG Molecular Diagnostics, Inc. shares have moved -6.28%, while the 5-day performance has seen it change -18.35%. Over the past 30 days, the shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) have changed 24.14%. Short interest in the company has seen 740.28 Million shares shorted with days to cover at 170.18.
Wall Street analysts have a consensus price target for the stock at $1.3, which means that the shares’ value could jump 88.02% from current levels. The projected low price target is $0.7 while the price target rests at a high of $2. In that case, then, we find that the current price level is +189.27% off the targeted high while a plunge would see the stock lose 1.24% from current levels.
HTG Molecular Diagnostics, Inc. (HTGM) estimates and forecasts
Figures show that HTG Molecular Diagnostics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -2.72% over the past 6 months, with this year growth rate of -39.22%, compared to 2.5% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 52.9% and 46.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be -41.2%.
4 analysts offering their estimates for the company have set an average revenue estimate of $1.79 Million for the current quarter. 4 have an estimated revenue figure of $2.96 Million for the next quarter concluding in September 01, 2020. Year-ago sales stood $5.56 Million and $5.41 Million respectively for this quarter and the next, and analysts expect sales will grow by -67.8% for the current quarter and -45.2% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +28% over the past 5 years. Earnings growth for 2020 is a modest +15.3% while over the next 5 years, the company’s earnings are expected to increase by 0%.
HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM)’s Major holders
Insiders own 7.87% of the company shares, while shares held by institutions stand at 58.1% with a share float percentage of 63.07%. Investors are also buoyed by the number of investors in a company, with HTG Molecular Diagnostics, Inc. having a total of 42 institutions that hold shares in the company. The top two institutional holders are Nantahala Capital Management, LLC with over 5.06 Million shares worth more than $1.64 Million. As of March 30, 2020, Nantahala Capital Management, LLC held 8.13% of shares outstanding.
The other major institutional holder is Cowen Prime Services LLC, with the holding of over 4.46 Million shares as of March 30, 2020. The firm’s total holdings are worth over $1.45 Million and represent 7.16% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Price (T.Rowe) Health Sciences Fund and Vanguard Total Stock Market Index Fund. As of December 30, 2019, the former fund manager holds about 1.7% shares in the company for having 1058876 shares of worth $743.23 Thousand while later fund manager owns 936.81 Thousand shares of worth $304.46 Thousand as of March 30, 2020, which makes it owner of about 1.51% of company’s outstanding stock.